BRPI0416289A - 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml) - Google Patents

4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)

Info

Publication number
BRPI0416289A
BRPI0416289A BRPI0416289-7A BRPI0416289A BRPI0416289A BR PI0416289 A BRPI0416289 A BR PI0416289A BR PI0416289 A BRPI0416289 A BR PI0416289A BR PI0416289 A BRPI0416289 A BR PI0416289A
Authority
BR
Brazil
Prior art keywords
cml
treatment
ome
quinolinecarbonitriles
anilino
Prior art date
Application number
BRPI0416289-7A
Other languages
English (en)
Inventor
Frank Charles Boschelli
Jennifer Michele Golas
Kim Timothy Arnt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0416289A publication Critical patent/BRPI0416289A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"4-ANILINO-3-QUINOLINACARBONITRILAS PARA O TRATAMENTO DE LEUCEMIA MIELóGENA CRÈNICA (CML)". Compostos da fórmula: onde: n é um inteiro de 1 a 3; X é N, CH, contanto que quando X for N, n seja 2 ou 3; R é alquila de 1 a 3 átomos de carbono; R¬ 1¬ é 2,4-diCl, 5-OMe; 2,4-diCl; 3,4,5-tri-OMe; 2-Cl, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-S-OMe, 2,4-diCl, 5-OEt; R¬ 2¬ é alquila de 1 a 2 átomos de carbono, e sais farmaceuticamente aceitáveis do mesmo.
BRPI0416289-7A 2003-11-06 2004-11-03 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml) BRPI0416289A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06
PCT/US2004/036722 WO2005046693A1 (en) 2003-11-06 2004-11-03 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Publications (1)

Publication Number Publication Date
BRPI0416289A true BRPI0416289A (pt) 2007-01-23

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416289-7A BRPI0416289A (pt) 2003-11-06 2004-11-03 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)

Country Status (18)

Country Link
US (2) US7417148B2 (pt)
EP (1) EP1680119A1 (pt)
JP (1) JP2007533655A (pt)
KR (1) KR20060118461A (pt)
CN (1) CN1874776A (pt)
AU (1) AU2004289243B2 (pt)
BR (1) BRPI0416289A (pt)
CA (1) CA2543163A1 (pt)
CO (1) CO5690608A2 (pt)
CR (1) CR8350A (pt)
EC (1) ECSP066548A (pt)
IL (1) IL175424A0 (pt)
MX (1) MXPA06004744A (pt)
NO (1) NO20062255L (pt)
RU (1) RU2006113691A (pt)
SG (1) SG146681A1 (pt)
WO (1) WO2005046693A1 (pt)
ZA (1) ZA200603596B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
MX2007016230A (es) * 2005-06-17 2008-03-06 Univ Texas Inhibicion de lesiones osteoliticas mediante inhibidores de quinasa src.
BRPI0611977A2 (pt) * 2005-06-24 2010-10-13 Wyeth Corp uso de um composto
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
US11103497B2 (en) * 2007-06-01 2021-08-31 Wyeth Llc Treatment of imatinib resistant leukemia
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2015123758A1 (en) 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
US20180000771A1 (en) 2015-01-13 2018-01-04 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2020209843A1 (en) 2019-04-09 2020-10-15 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Also Published As

Publication number Publication date
ZA200603596B (en) 2009-12-30
KR20060118461A (ko) 2006-11-23
AU2004289243A1 (en) 2005-05-26
AU2004289243B2 (en) 2010-07-22
NO20062255L (no) 2006-08-01
IL175424A0 (en) 2008-04-13
JP2007533655A (ja) 2007-11-22
US7417148B2 (en) 2008-08-26
US20100029677A1 (en) 2010-02-04
US7919625B2 (en) 2011-04-05
SG146681A1 (en) 2008-10-30
MXPA06004744A (es) 2006-07-05
CR8350A (es) 2006-10-06
ECSP066548A (es) 2006-10-17
WO2005046693A1 (en) 2005-05-26
EP1680119A1 (en) 2006-07-19
CN1874776A (zh) 2006-12-06
RU2006113691A (ru) 2007-12-20
US20050101780A1 (en) 2005-05-12
CO5690608A2 (es) 2006-10-31
CA2543163A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
ECSP066548A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica
ATE503746T1 (de) Neue imidazolidinderivate
BR0109851A (pt) Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste
BR0109703A (pt) Derivados de piperazina
ATE516326T1 (de) Kautschukmischungen
CY1105766T1 (el) Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων
TW200716650A (en) Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
ECSP055972A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE602005005240D1 (de) 4'-C-substituierte 2-Haloadenosinderivate
EA200801945A1 (ru) Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы
CY1112107T1 (el) Νεα ενωση πυριδαζινης και χρηση αυτης
WO2009047298A3 (en) Dimers of harmol or of its derivatives and uses thereof
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
BR0214842A (pt) Inibidores de integrase hiv
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
UY27979A1 (es) Indoles sustituidos en posición 2,4
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
DE60112960D1 (de) Kondensierte pyridoindolderivate
BRPI0412159A (pt) emprego
BR0213465A (pt) Compostos de 4-imidazolin-2-ona
BR0102377A (pt) Inibidores de não-nucleosìdeo transcriptase reversa
BRPI0510625A (pt) tienopiridinas como inibidores de ikk

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL